Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2021 | 1 |
2023 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
The following term was not found in PubMed: Terkenli
Page 1
Training Excitatory-Inhibitory Recurrent Neural Networks for Cognitive Tasks: A Simple and Flexible Framework.
PLoS Comput Biol. 2016 Feb 29;12(2):e1004792. doi: 10.1371/journal.pcbi.1004792. eCollection 2016 Feb.
PLoS Comput Biol. 2016.
PMID: 26928718
Free PMC article.
However, existing RNNs lack basic biological features such as the distinction between excitatory and inhibitory units (Dale's principle), which are essential if RNNs are to provide insights into the operation of biological circuits. ...We provide an implementation based on …
However, existing RNNs lack basic biological features such as the distinction between excitatory and inhibitory units (Dale's princip …
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M, Sklirou AD, Ntanasis-Stathopoulos I, Darmani I, Briasoulis A, Kastritis E, Angelopoulou M, Baltadakis I, Panayiotidis P, Trougakos IP, Vassilakopoulos TP, Pagoni M, Dimopoulos MA.
Terpos E, et al.
Cancers (Basel). 2021 Sep 6;13(17):4480. doi: 10.3390/cancers13174480.
Cancers (Basel). 2021.
PMID: 34503290
Free PMC article.
We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutra …
We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's l …
Item in Clipboard
Cite
Cite